Literature DB >> 27768093

The role of maintenance therapy in multiple myeloma.

B Lipe1, R Vukas2, J Mikhael3.   

Abstract

Multiple myeloma is the second most common type of blood cancer and remains incurable despite advances in therapy. Current therapy for multiple myeloma includes a phased-approach, often consisting of initial induction therapy, consolidation and maintenance therapy. With an ever-growing landscape of treatment options, the approach to optimal therapy has become increasingly complex. Specifically, controversy surrounds the optimal use and duration of maintenance therapy. We conducted a comprehensive literature search to analyze the most current literature and to provide recommendations for maintenance therapy in multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27768093      PMCID: PMC5098261          DOI: 10.1038/bcj.2016.89

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN: 2044-5385            Impact factor:   11.037


  39 in total

1.  Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

Authors:  Paul G Richardson; Sundar Jagannath; Philippe Moreau; Andrzej J Jakubowiak; Marc S Raab; Thierry Facon; Ravi Vij; Darrell White; Donna E Reece; Lotfi Benboubker; Jeffrey Zonder; L Claire Tsao; Kenneth C Anderson; Eric Bleickardt; Anil K Singhal; Sagar Lonial
Journal:  Lancet Haematol       Date:  2015-11-16       Impact factor: 18.959

2.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

3.  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Authors:  Pieter Sonneveld; Ingo G H Schmidt-Wolf; Bronno van der Holt; Laila El Jarari; Uta Bertsch; Hans Salwender; Sonja Zweegman; Edo Vellenga; Annemiek Broyl; Igor W Blau; Katja C Weisel; Shulamiet Wittebol; Gerard M J Bos; Marian Stevens-Kroef; Christof Scheid; Michael Pfreundschuh; Dirk Hose; Anna Jauch; Helgi van der Velde; Reinier Raymakers; Martijn R Schaafsma; Marie-Jose Kersten; Marinus van Marwijk-Kooy; Ulrich Duehrsen; Walter Lindemann; Pierre W Wijermans; Henk M Lokhorst; Hartmut M Goldschmidt
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

4.  Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

Authors:  Joaquin Martinez-Lopez; Joan Blade; María-Victoria Mateos; Carlos Grande; Adrián Alegre; José García-Laraña; Anna Sureda; Javier de la Rubia; Eulogio Conde; Rafael Martinez; Felipe de Arriba; Maria C Viguria; Joan Besalduch; Rafael Cabrera; José D Gonzalez-San Miguel; José Luis Guzman-Zamudio; Maria Carmen Gomez del Castillo; José Maria Moraleda; Juan C García-Ruiz; Jesús San Miguel; Juan José Lahuerta
Journal:  Blood       Date:  2011-04-11       Impact factor: 22.113

5.  Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

Authors:  Antonio Palumbo; Sara Bringhen; Alessandra Larocca; Davide Rossi; Francesco Di Raimondo; Valeria Magarotto; Francesca Patriarca; Anna Levi; Giulia Benevolo; Iolanda Donatella Vincelli; Mariella Grasso; Luca Franceschini; Daniela Gottardi; Renato Zambello; Vittorio Montefusco; Antonietta Pia Falcone; Paola Omedé; Roberto Marasca; Fortunato Morabito; Roberto Mina; Tommasina Guglielmelli; Chiara Nozzoli; Roberto Passera; Gianluca Gaidano; Massimo Offidani; Roberto Ria; Maria Teresa Petrucci; Pellegrino Musto; Mario Boccadoro; Michele Cavo
Journal:  J Clin Oncol       Date:  2014-01-21       Impact factor: 44.544

6.  PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Authors:  Paul G Richardson; Robert L Schlossman; Melissa Alsina; Donna M Weber; Steven E Coutre; Cristina Gasparetto; Sutapa Mukhopadhyay; Michael S Ondovik; Mahmudul Khan; Carole S Paley; Sagar Lonial
Journal:  Blood       Date:  2013-08-15       Impact factor: 22.113

7.  Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

Authors:  Antonio Palumbo; Francesca Gay; Federica Cavallo; Francesco Di Raimondo; Alessandra Larocca; Izhar Hardan; Arnon Nagler; Maria T Petrucci; Roman Hajek; Sara Pezzatti; Michel Delforge; Francesca Patriarca; Francesca Donato; Chiara Cerrato; Chiara Nozzoli; Zhinuan Yu; Luana Boccadifuoco; Tommaso Caravita; Giulia Benevolo; Tommasina Guglielmelli; Donatella Vincelli; Christian Jacques; Meletios A Dimopoulos; Giovannino Ciccone; Pellegrino Musto; Paolo Corradini; Michele Cavo; Mario Boccadoro
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

8.  Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.

Authors:  Pieter Sonneveld; Hartmut Goldschmidt; Laura Rosiñol; Joan Bladé; Juan José Lahuerta; Michele Cavo; Paola Tacchetti; Elena Zamagni; Michel Attal; Henk M Lokhorst; Avinash Desai; Andrew Cakana; Kevin Liu; Helgi van de Velde; Dixie-Lee Esseltine; Philippe Moreau
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

9.  GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

Authors:  María-Victoria Mateos; Albert Oriol; Joaquín Martínez-López; Ana-Isabel Teruel; Ana López de la Guía; Javier López; Enrique Bengoechea; Montserrat Pérez; Rafael Martínez; Luis Palomera; Felipe de Arriba; Yolanda González; José Mariano Hernández; Miquel Granell; José-Luis Bello; Joan Bargay; Francisco-Javier Peñalver; María-Luisa Martín-Mateos; Bruno Paiva; María-Angeles Montalbán; Joan Bladé; Juan-Jose Lahuerta; Jesús F San-Miguel
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

10.  Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.

Authors:  Sonja Zweegman; Bronno van der Holt; Ulf-Henrik Mellqvist; Morten Salomo; Gerard M J Bos; Mark-David Levin; Heleen Visser-Wisselaar; Markus Hansson; Annette W G van der Velden; Wendy Deenik; Astrid Gruber; Juleon L L M Coenen; Torben Plesner; Saskia K Klein; Bea C Tanis; Damian L Szatkowski; Rolf E Brouwer; Matthijs Westerman; M Rineke B L Leys; Harm A M Sinnige; Einar Haukås; Klaas G van der Hem; Marc F Durian; E Vera J M Mattijssen; Niels W C J van de Donk; Marian J P L Stevens-Kroef; Pieter Sonneveld; Anders Waage
Journal:  Blood       Date:  2016-01-22       Impact factor: 22.113

View more
  10 in total

1.  Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan.

Authors:  Yutaka Tsukune; Makoto Sasaki; Takeshi Odajima; Kazutaka Sunami; Tomomi Takei; Yukiyoshi Moriuchi; Masaki Iino; Atsushi Isoda; Aya Nakaya; Tsuyoshi Muta; Takaaki Miyake; Koji Miyazaki; Takayuki Shimizu; Kei Nakajima; Aiko Igarashi; Koji Nagafuji; Taro Kurihara; Tomonori Aoyama; Hiroki Sugimori; Norio Komatsu
Journal:  Blood Cancer J       Date:  2017-11-23       Impact factor: 11.037

2.  Epidemiology of multiple myeloma in 17 Latin American countries: an update.

Authors:  Maria Paula Curado; Max M Oliveira; Diego R M Silva; Dyego L B Souza
Journal:  Cancer Med       Date:  2018-03-24       Impact factor: 4.452

3.  Characteristics and outcomes of patients with multiple myeloma : Data from a developing country.

Authors:  Abdul Hameed; Jamshed Ali; Kiran Munawar; Farah Arshad; Farhana Badar; Neelam Siddiqui
Journal:  Med J Islam Repub Iran       Date:  2018-02-01

4.  Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.

Authors:  Rafat Abonour; Lynne Wagner; Brian G M Durie; Sundar Jagannath; Mohit Narang; Howard R Terebelo; Cristina J Gasparetto; Kathleen Toomey; James W Hardin; Amani Kitali; Craig J Gibson; Shankar Srinivasan; Arlene S Swern; Robert M Rifkin
Journal:  Ann Hematol       Date:  2018-07-29       Impact factor: 3.673

5.  A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.

Authors:  Jesús F San-Miguel; Maria-Asunción Echeveste Gutierrez; Ivan Špicka; María-Victoria Mateos; Kevin Song; Michael D Craig; Joan Bladé; Roman Hájek; Christine Chen; Alessandra Di Bacco; Jose Estevam; Neeraj Gupta; Catriona Byrne; Vickie Lu; Helgi van de Velde; Sagar Lonial
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941

6.  Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy.

Authors:  Graham Jackson; Jayne Galinsky; David E C Alderson; Vijay K D'Souza; Vanessa Buchanan; Sujith Dhanasiri; Simon Walker
Journal:  Eur J Haematol       Date:  2019-08-12       Impact factor: 2.997

Review 7.  Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials.

Authors:  Xinrong Xiang; Qiao He; Yang Ou; Wen Wang; Yu Wu
Journal:  Front Pharmacol       Date:  2020-12-03       Impact factor: 5.810

8.  A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncology.

Authors:  Rahma Warsame; Joselle Cook; Briant Fruth; Joleen Hubbard; Katrina Croghan; Katharine A R Price; Aminah Jatoi; Shaji Kumar; Carrie Thompson; Jan Buckner; Angela Dispenzieri; Jeff Sloan; Amylou C Dueck
Journal:  Contemp Clin Trials Commun       Date:  2022-07-13

Review 9.  Integrating Emerging Data Into Clinical Practice: A Case-Based Approach for Multiple Myeloma.

Authors:  Sandra Kurtin
Journal:  J Adv Pract Oncol       Date:  2017-05-01

Review 10.  Chimeric antigen receptor T cell therapies for multiple myeloma.

Authors:  Chao Wu; Lina Zhang; Qierra R Brockman; Fenghuang Zhan; Lijuan Chen
Journal:  J Hematol Oncol       Date:  2019-11-21       Impact factor: 17.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.